伊马替尼治疗慢性粒细胞白血病的临床效果研究OA
Clinical effect research of imatinib in the treatment of chronic myelocytic leukemia
目的:观察伊马替尼治疗慢性粒细胞白血病(CML)的临床效果及安全性。方法慢性期(CML-CP)患者IM中位剂量为400 mg/d,加速期(CML-AP)患者中位剂量为600 mg/d,对于急变期(CML-BP)患者采用IM+HAG联合治疗方案即IM 600 mg/d联合高三尖杉酯碱2 mg/d,阿糖胞苷25 mg,1次/12 h,粒细胞集落刺激因子200μg/m2。治疗过程中根据患者血常规和药物不良反应严重程度及时调整药物剂量或暂停用药。治疗初期…查看全部>>
Objective To observe clinical effect and safety of imatinib (IM)in the treatment of chronic myelocytic leukemia (CML). Methods IM median dose of CML chronic phase (CML-CP)patient was 400 mg/d.IM median dose of CML accelerated phase(CML-AP)patientwas 600 mg/d.IM+HAG combination therapy scheme including IM(600 mg/d), homoharringtonine(2 mg/d),cytarabine (25 mg,1once/12 h),granulocyte colony stimulating factor(200 g/m2) were used in CML blastic phase(CML-BP).Th…查看全部>>
余霞
成都市第五人民医院血液科,成都 611130
医药卫生
慢性粒细胞白血病伊马替尼慢性期加速期急变期疗效
Chronic myelocytic leukemiaImatinibChronic phaseAccelerated phaseBlastic phaseCurative effect
《中国当代医药》 2014 (24)
105-107,3
评论